33295-47-5Relevant academic research and scientific papers
BENZOINDAZOLONE COMPOUND, AND INTERMEDIATE THEREOF
-
, (2022/01/12)
The present invention relates to a benzoindazolone compound, or a pharmaceutically acceptable salt, hydrate, solvate, enantiomer, diasteromer, tautomer or prodrug thereof; and an intermediate thereof. A compound according to the present invention is used as a substrate for NQO1 to facilitate a redox reaction of NQO1, and thus is expected to be developable as a medicine for preventing or treating inflammatory diseases.
TARGETED RADIOPHARMACEUTICALS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER
-
Page/Page column 311, (2021/01/29)
A compound of general formula (I): wherein: n is 1, 2 or 3; R1, R2, R3 and R4, independently represent OH or Q; and 20 Q represents a tissue-targeting moeity selected from the group consisting of or a stereoisomer, a hydrate, a solvate, or a salt thereof, or a mixture of same, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said 25 compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of soft tissue diseases, as a sole agent or in combination with other active ingredients.
1-Methoxyisobenzofuran: Formation from 1,3-Dihydro-1,1-dimethoxyisobenzofuran
Makhlouf, Mansour A.,Rickborn, Bruce
, p. 2734 - 2739 (2007/10/02)
1-Methoxyisobenzofuran is formed by treatment of 1,3-dihydro-1,1-dimethoxyisobenzofuran with either a trace of acetic acid in refluxing toluene or with LDA at 70 deg C.The requirements to obtain Diels-Alder adducts under both sets of conditions are examined, and various products are characterized.
